Efficacy of botulinotherapy in the treatment of the lower limb spasti-city


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article reviews current perception on etiology and pathogenesis of lower limb spastic paresis as one of the most disabling pathologic condition, leading to a significant limitation of daily activity and independence. The main pathological patterns of lower limb spasticity depending on the etiology are described. Results of large-scale randomized clinical trials evaluating efficacy and safety of botulinum toxin A (BTA) - Dysport (abobotulinumtoxin A) for the treatment of lower limb spasticity of different etiology are presented. The article contains an analysis of optimal rehabilitation approaches using BTA in patients with lower limb spasticity. Authors came to a conclusion that abobotulinumtoxinA treatment in patients with lower limb spastic paresis, independently of the underlying pathology, is an effective method with a favorable safety profile. Abobotulinumtoxin A should be regarded as an obligatory component of standard rehabilitation protocols with high level of evidence. However, further studies are needed to determine optimal dosing schemes, target muscle groups and the most effective rehabilitation approaches.

Texto integral

Acesso é fechado

Sobre autores

S. Khatkova

Treatment and Rehabilitation Center, Moscow; SRC Burnasyan Federal Medical Biophysical Center

Email: Hse15@mail.ru
MD, Prof.

M. Akulov

N.N. Burdenko National Scientific and Practical Center for Neurosurgery

V. Zakharov

N.N. Burdenko National Scientific and Practical Center for Neurosurgery

A. Orlova

I.M.Sechenov First Moscow State Medical University (Sechenov University)

L. Krylova

Hospital for War Veterans, Naberezhnye Chelny

A. Balbert

Sverdlovsk Regional Clinical Psychoneurological Hospital for War Veterans

V. Dyagileva

Federal Clinical Research Center for Intensive Care Medicine and Rehabilitology

E. Nikolayev

Treatment and Rehabilitation Center, Moscow

Bibliografia

  1. Gracies J.M. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005;31(5):552-71.
  2. SPASM, E.T.N.t.D.S.M.o.S. Centre for Rehabilitation and Engineering Studies University of Newcastle Stephenson Building Claremont Road Newcastle upon Tyne NE1 7RU UK. 2006.
  3. Тимербаева С.Л., Орлова О.Р., Хатькова С.Е. и др. Азбука ботулинотерапии: научно- практическое издание / Под ред. С.Л. Тимербаевой. М., 2014. 416 с.
  4. Хатькова С.Е., Орлова О.Р., Боцина А.Ю. и др. Основные принципы ведения пациентов с нарушением мышечного тонуса после очагового повреждения головного мозга. Consilium Medicum. 2016;18(2-1):25-33.
  5. Клинические рекомендации: Очаговое повреждение головного мозга у взрослых: синдром спастичности / Под ред. Е. Хатьковой. М., 2017. 95 с.
  6. Brashear A. Spasticity: diagnosis and management. 2nd ed. New York: Demos Medical Publishing. 2016. Р. 495.
  7. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Neurology A.o.C.PI.i., Spasticity in adults: management using botulinum toxin. National Guidelines, London: RCP 2009.
  8. Dressler D., Bhidayasiri R., Bohlega S., et al. Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J. Neurol. 2017;264(1):112-20.
  9. Cioncoloni D., Taddei S., Bielli S., et al. Meaningful improvement in walking performance after Botulinum neurotoxinA (BoNT-A) in chronic spastic patients. NeuroRehabilitation. 2014;34(1):185-92.
  10. Aaslund M.K., Moe-Nilssen R., Gjelsvik B.B., et al. A longitudinal study investigating how stroke severity, disability, and physical function the first week post-stroke are associated with walking speed six months post-stroke. Physiother Theory Pract. 2017;33(12): 932-42.
  11. Outermans J., Pool J., van de Port I., et al. What's keeping people after stroke from walking outdoors to become physically active? A qualitative study, using an integrated biomedical and behavioral theory of functioning and disability. BMC. Neurol. 2016; 16(1):137.
  12. Shimada H., Makizako H., Doi T., et al. Incidence of Disability in Frail Older Persons With or Without Slow Walking Speed. J. Am. Med. Dir. Assoc. 2015;16(8):690-96.
  13. Martin A., Abogunrin S., Kurth H., Dinet J. Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr. Dis. Treat. 2014;10:111-22.
  14. Hara Y. Deep venous thrombosis in stroke patients during rehabilitation phase. Keio J. Med. 2008;57(4):196-204.
  15. Atiyeh B.S., Hayek S.N. Pressure sores with associated spasticity: a clinical challenge. Int. Wound J. 2005;2(1):77-80.
  16. Рассеянный склероз Клиническое руководство / Под. ред. Е.И. Гусева, И.А. Завалишина, А.Н. Бойко. М., 2011. 528 с.
  17. Esquenazi A., Alfaro A., Ayyoub Z., et al. OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach. PMR. 2017;9(10):960-68.
  18. Гусев Е.И., Бойко А.Н., Костенко Е.В. Спастичность: клиника, диагностика и комплексная реабилитация с применением ботулинотерапии. М., 2017. 272 с.
  19. Hoare B.J., Wallen M.A., Imms C., et al. Botulinumtoxin A as an adjunct to treatment in themanagement of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev. 2010;CD003469.
  20. McIntyre A., Lee T., Janzen S., et al. Systematic review of the effectiveness of pharmacological interventions in the treatment of spasticity of the hemiparetic lower extremity more than six months post stroke. Top. Stroke Rehabil. 2012;19:479-90.
  21. Ng Y., Chew E., Samuel G., et al. Advances in rehabilitation medicine, Singapore Med. J. 2013;54:538-51.
  22. Schramm A., Ndayisaba J., auf dem Brinke M., et al. Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry. J. Neural. Transm. 2014;121:521-30.
  23. Simpson D.M., Hallett M., Ashman E.J., et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-26.
  24. Gracies J.M., Brashear A., Jech R., et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015;14(10):992-1001.
  25. Gracies J.M., O'Dell M., Vecchio M., et al. Effects of repeated abobotulinumtoxinA injections in upper limb spasticity. Muscle Nerve. 2018;57(2):245-54.
  26. Brashear A., Gordon M.F., Elovic E., et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N. Engl. J. Med. 2002; 347(6):395-400.
  27. Gracies J.M., Esquenazi A., Brashear A., et al. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017;89(22): 2245-53.
  28. Mauricio R. AbobotulinumtoxinA time to retreatment in spasticity: An analysis from 3 Phase 3 spasticity studies. AAPM&R Poster P71. 2017. Ann. Assembly in Denver, CO.
  29. Pittock S.J., Moore A.P., Hardiman O., et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc. Dis. 2003;15(4):289-300.
  30. Amatya B., Khan F., Ng L., Galea M. Rehabilitation for people withmultiple sclerosis: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews 2017;7:CD012732.
  31. Гусев Е.И., Завалишин И.А., Бойко А.Н., Захарова М.Н. Демиелинизирующие заболевания центральной нервной системы. «Неврология (национальное руководство, 2-е издание)» / Под ред. Е.И. Гусева, А.Н. Коновалова, В.И. Скворцовой. М., 2018:448-502
  32. Hyman N., Barnes M., Bhakta B., et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J. Neurol. Neurosurg. Psychiatry. 2000;68(6):707-12.
  33. Gusev Y.I., Banach M., Simonow A., et al. Efficacy and safety of botulinum type a toxin in adductor spasticity due to multiple sclerosis. J. Musculoskeletal. Pain. 2008;16(3):175-88.
  34. Dressler D., Bhidayasiri R., Bohlega S., et al. Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J. Neurol. 2016;264(1):112-20.
  35. Dashtipour K., Chen J.J., Walker H.W., Lee M.Y. Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity. Medicine (Baltimore). 2016;95(2):2468.
  36. Turner-Stokes L., Fheodoroff K., Jacinto J., Maisonobe P. Results from the Upper Limb International Spasticity Study-ll (ULIS-II): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open. 2013. № 3. Р 2771.
  37. Hesse S., Jahnke M.T., Luecke D., et al. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci. left. 1995;201:37-40.
  38. Alkandari S. Evaluation of walking speed (10m walking test) in patients with chronic hemiparesis after at least 3 consecutive botulinum neurotoxin injections while patients follow a guided self-rehabilitation contract. Ann. Phys. Rehabilit. Med. 2011;54:243.
  39. Gracies J.M. The Concept of Guided Self-Rehabilitation Contracts in the Treatment of Deforming Spastic Paresis. Phys. Med. Rehabil. Kuror. 2015;25-6.
  40. Gracies J.M. Coefficients of impairment in deforming spastic paresis. Ann. Phys. Rehabil. Med. 2015;58(3):173-78.
  41. Khalil N., Hutin E., Santiago T., et al. Guided self-rehabilitation contracts and gait speed in chronic hemiparesis. A prospective study. Ann. Phys. Rehabil. Med. 2013;56(Suppl. 1):45-6.
  42. Gracies J.M., O'Dell M., Vecchio M., et al. Effects of repeated abobotulinumtoxinA injections in upper limb spasticity. Muscle Nerve. 2018;57(2):245-54.
  43. Gracies J.M. Effect on voluntary movements of simultaneous upper and lower limb abobotulinumtoxin A injections in conjunction with Guided Self-rehabilitation Contracts in adults with spastic hemiparesis: methodology of the ENGAGE study. AAPM&R Poster. Ann. Assembly, Denver. 2017. 62 p.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies